Inventor
PHOGAT SANJAY K
US23 patents
⚠️ This page may combine multiple inventors who share the name “PHOGAT SANJAY K”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
THERACLONE SCIENCES INC
12 patentsUS10087239B2Oct 2, 2018
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
THERACLONE SCIENCES INC14 citations91
US9464131B2Oct 11, 2016
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
THERACLONE SCIENCES INC18 citations91
US11319362B2May 3, 2022
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
THERACLONE SCIENCES INC3 citations83
US10865234B2Dec 15, 2020
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC1 citations72
US10836811B2Nov 17, 2020
Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
THERACLONE SCIENCES INC1 citations72
US10407493B2Sep 10, 2019
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC1 citations72
US12312396B2May 27, 2025
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC0 citations62
US12018067B2Jun 25, 2024
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC0 citations62
US11584789B2Feb 21, 2023
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC0 citations62
US11845789B2Dec 19, 2023
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
THERACLONE SCIENCES INC0 citations61
US10239934B2Mar 26, 2019
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC0 citations51
US9920111B2Mar 20, 2018
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
THERACLONE SCIENCES INC0 citations51
INT AIDS VACCINE INITIATIVE
5 patentsUS10844095B2Nov 24, 2020
Recombinant viral vectors
INT AIDS VACCINE INITIATIVE0 citations50
US10202424B2Feb 12, 2019
Recombinant viral vectors
INT AIDS VACCINE INITIATIVE0 citations50
US9802986B2Oct 31, 2017
Recombinant viral vectors
INT AIDS VACCINE INITIATIVE0 citations50
US9796774B2Oct 24, 2017
HIV-1 broadly neutralizing antibodies
INT AIDS VACCINE INITIATIVE0 citations50
US9382311B2Jul 5, 2016
HIV-1 broadly neutralizing antibodies
INT AIDS VACCINE INITIATIVE0 citations50
INT AIDS VACCINE INITIATIVE INC
2 patentsUS12410243B2Sep 9, 2025
Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
INT AIDS VACCINE INITIATIVE INC2 citations73
US11891416B2Feb 6, 2024
Recombinant viral vectors
INT AIDS VACCINE INITIATIVE INC0 citations60